Mat-Ly-Lu Xenograft Rat Model Service for Prostate Cancer

The Mat-Ly-Lu syngeneic rat model is a highly metastatic, androgen-dependent prostate adenocarcinoma platform derived from the historic Dunning R-3327 series, offering intact immune surveillance and spontaneous dissemination to lung, lymph node, and bone within a compressed study timeline. Alfa Cytology leverages authenticated Mat-Ly-Lu cell stocks and standardized Copenhagen rat implantation protocols to construct robust preclinical cohorts, supporting anti-metastatic therapy evaluation, androgen-axis drug screening, and multidrug-resistance mechanism studies with integrated imaging and histopathological endpoints.

Overview of Mat-Ly-Lu Xenograft Rat Model for Prostate Cancer

The Mat-Ly-Lu cell line belongs to the Dunning R-3327 system, a collection of rat prostate carcinoma sublines originally isolated by Isaacs and colleagues in 1963 from a spontaneous prostatic adenocarcinoma arising in an aged inbred Copenhagen rat. Mat-Ly-Lu was subsequently derived through successive in vivo passages of the AT-1 tumor line, selecting for progressively more aggressive phenotypes. Histologically, the cells display anaplastic, poorly differentiated adenocarcinoma morphology with epithelial-to-mesenchymal transition (EMT) characteristics, including loss of contact inhibition, multi-layered growth, and spindle-shaped invasive motility. The line retains androgen dependence, making it uniquely suited for studying castration-resistant progression and androgen-deprivation therapy responses.

Fig 1. Development of primary tumour and metastases from subcutaneous inoculation of Mat-LyLu cells in the Dunning model of rat prostate cancer. (Bugan, Ilknur, et al., 2019)

A defining feature of the Mat-Ly-Lu model is its exceptionally high metastatic potential—exceeding 90% in syngeneic Copenhagen recipients—with predictable dissemination to the lungs, inguinal lymph nodes, spleen, kidney, liver, and bone (femur and lumbar spine). This metastatic pattern closely mirrors the visceral and osseous spread observed in advanced human prostate cancer. Additionally, the line exhibits pronounced multidrug resistance driven by elevated rat mdr1b gene expression, the homologue of human MDR1, rendering it a stringent platform for evaluating novel chemotherapeutics, liposomal drug formulations, prodrugs, and metronomic dosing strategies. The model is further amenable to luciferase transduction, enabling sensitive, non-invasive bioluminescence tracking of both primary tumor growth and occult metastatic lesions.

Cell Line Information: Mat-Ly-Lu

The table below summarizes the authenticated characteristics of the Mat-Ly-Lu rat prostate adenocarcinoma cell line, compiled from established cell repositories and peer-reviewed literature.

Our Services

Alfa Cytology operationalizes the Mat-Ly-Lu platform through a fully documented preclinical pipeline: authenticated cell banking under low-passage conditions, surgical implantation by experienced veterinary surgeons in subcutaneous, intraprostatic, or intratibial configurations, longitudinal tumor monitoring via caliper and bioluminescence imaging, and terminal multi-organ histopathology with quantitative metastatic burden analysis. Every study is designed to align with your compound's mechanism of action, whether targeting androgen signaling, metastatic dissemination, or multidrug-resistance pathways, with all work conducted under accredited IACUC oversight and GLP-aligned documentation standards.

Workflow of Mat-Ly-Lu Xenograft Rat Model Construction

Construction of the Mat-Ly-Lu syngeneic prostate cancer model follows a reproducible surgical and cell-biology workflow optimized for high tumor take rates, consistent metastatic progression, and minimal perioperative morbidity. The protocol can be adapted for subcutaneous flank, orthotopic intraprostatic, or intratibial bone metastasis implantation depending on the scientific objective.

1. Cell Line Resuscitation & Quality Control: Cryopreserved Mat-Ly-Lu stocks are thawed and expanded in complete growth medium under antibiotic-free, low-passage conditions. Cell identity is confirmed by morphology—specifically anaplastic epithelial features with EMT characteristics—and growth curve analysis. Harvest occurs at 70–80% confluence using 0.25% trypsin-EDTA; viability is assessed by trypan blue exclusion, with only suspensions exceeding 95% viability advanced to implantation. Cells are washed in PBS and resuspended in serum-free medium at a concentration of 1 × 10⁶ cells per 100 µL for subcutaneous injection, or at 5 × 10⁵ cells per 50 µL for orthotopic delivery.
2. Recipient Preparation & Anesthesia: Adult male Copenhagen rats (typically 8–12 weeks old, 200–250 g) are acclimated for one week prior to surgery. On the day of implantation, animals are anesthetized with isoflurane inhalation (2–3% in oxygen) or ketamine/xylazine cocktail, with continuous monitoring of respiratory rate and pedal reflex. Ophthalmic ointment is applied to prevent corneal desiccation, and the surgical field is shaved and disinfected with alternating betadine and ethanol scrubs.
3. Tumor Cell Implantation: For subcutaneous models, 100 µL of the Mat-Ly-Lu single-cell suspension (1 × 10⁶ cells) is injected into the right flank using a 25-gauge needle. For orthotopic intraprostatic models, a midline laparotomy is performed; the prostate is exteriorized, and 50 µL of cell suspension (5 × 10⁵ cells) is injected into the dorsal lobe using a 30-gauge Hamilton syringe. For bone metastasis modeling, 20 µL of cell suspension (2 × 10⁵ cells) is delivered into the tibial marrow cavity after cortical drilling. The injection site is sealed with surgical adhesive, and the incision is closed with absorbable suture. Analgesia (buprenorphine, 0.05–0.1 mg/kg) is administered subcutaneously immediately post-surgery.
4. Post-Operative Monitoring & Tumor Tracking: Animals are housed individually or in small groups on warming pads until fully conscious. Body weight, food intake, and incision integrity are monitored daily for the first 72 hours, then twice weekly. Subcutaneous tumors are measured with digital calipers (volume = L × W² / 2) from first palpable detection, typically 7–10 days post-implantation. For luciferase-transduced Mat-Lu ELN variants, bioluminescence imaging is performed weekly following intraperitoneal D-luciferin injection (150 mg/kg), capturing total flux as a quantitative surrogate of viable tumor and metastatic cell burden. Clinical signs of metastatic progression—including respiratory distress, hind-limb paralysis, or weight loss—are recorded.
5. Therapeutic Intervention & Endpoint Harvest: Upon reaching the target tumor volume (typically 100–200 mm³ for subcutaneous; 50–100 mm³ for orthotopic by imaging) or defined metastatic burden, animals are randomized into treatment and control cohorts. Test articles are administered according to the sponsor-defined regimen—intravenous, oral gavage, intraperitoneal, intratumoral, or via jugular vein catheter for metronomic infusion. Tumor measurements continue on schedule until the study endpoint. At termination, animals are humanely euthanized. Primary tumors, lungs, inguinal lymph nodes, spleen, liver, kidneys, femurs, and lumbar spine are harvested. Tumor weight is recorded, tissues are digitally imaged, and samples are processed for H&E histopathology, Ki-67 proliferation index, TUNEL apoptosis scoring, and metastatic burden quantification by luciferase assay or human/rat-specific marker immunohistochemistry.

Fig 2. Mat-Ly-Lu Xenograft Rat Model construction workflow.

Case Study-Mat-Ly-Lu Xenograft Rat Model Development

In a recent preclinical program, Alfa Cytology utilized the Mat-Ly-Lu subcutaneous syngeneic model to evaluate the anti-metastatic efficacy of a novel liposomal docetaxel formulation in androgen-dependent prostate cancer. Following authenticated Mat-Ly-Lu cell expansion and flank implantation into Copenhagen rats, primary tumors were permitted to establish for 14 days prior to randomization into vehicle, free docetaxel, and liposomal-encapsulated docetaxel cohorts. The liposomal formulation was administered intravenously on a weekly schedule, with longitudinal primary tumor volume monitoring by caliper and interim bioluminescence imaging to track occult metastatic seeding. Terminal analyses included primary tumor H&E histopathology, lung and bone metastasis quantification by ex vivo luciferase assay, Ki-67 proliferation index, and TUNEL apoptosis scoring in metastatic nodules. The dataset revealed a significant reduction in metastatic burden to lung and lumbar spine relative to the free drug arm, accompanied by sustained primary tumor growth delay, furnishing the sponsor with pharmacodynamic evidence to support formulation optimization and downstream IND-enabling studies.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your preclinical partner for Mat-Ly-Lu prostate cancer model development means gaining access to a specialized infrastructure that de-risks the syngeneic workflow and sharpens translational relevance for metastatic and hormone-refractory disease.

• Authenticated Mat-Ly-Lu master and working cell banks are maintained under documented low-passage protocols to minimize genetic drift and preserve the high metastatic potential and androgen-dependent phenotype prior to implantation.
• Our surgical team has performed hundreds of rat prostate implantations—including subcutaneous, orthotopic intraprostatic, and intratibial bone metastasis routes—achieving high tumor take rates with low perioperative mortality through refined anesthesia and post-operative care.
• The syngeneic Copenhagen host retains intact immune surveillance, enabling robust evaluation of immune-modulatory agents, oncolytic viruses, and combination regimens that depend on functional T-cell, macrophage, and natural killer cell populations.
• Integrated bioluminescence imaging capabilities support real-time, longitudinal tracking of luciferase-transduced Mat-Lu ELN primary tumors and occult metastatic lesions with sensitivity superior to conventional imaging alone.
• Multi-organ endpoint packages encompass lung, lymph node, bone, liver, and kidney metastasis quantification by luciferase assay, histopathology, and immunohistochemistry, collapsing the timeline from study completion to data delivery.
• All procedures are conducted under fully accredited IACUC oversight with comprehensive veterinary support, ensuring ethical rigor and regulatory readiness for IND-supporting packages.

Contact Us

If your prostate cancer therapeutic program demands a preclinical model that bridges primary tumor biology with spontaneous metastatic dissemination to bone and visceral organs in an immunocompetent host, reach out to us today. The Alfa Cytology scientific team is ready to review your target profile, propose a customized Mat-Ly-Lu study design with integrated metastasis-monitoring endpoints, and provide a detailed timeline and quotation aligned with your development milestones. Contact us now to move your compound from bench to preclinical proof-of-concept with the confidence that only a specialized oncology CRO can deliver.

For research use only. Not intended for any clinical use.